Tirzepatide compounding outcome

Resolution

Rule

This market resolves YES if the FDA issues a final written position statement on the regulatory status of compounded tirzepatide by December 31, 2026. Source: FDA official guidance documents, Federal Register, or FDA.gov public announcements. If no final position is issued by the deadline, this market resolves NO.

Source: https://www.fda.gov/

Resolves by Jan 28, 2027.